The most notable advancement in cellular immunotherapies for CLL was the March 2024 FDA approval of liso-cel for patients who progressed after at least two lines of therapy including a BTKi and BCL-2 inhibitor [139]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.